Leading MEP declares Parkinson’s “a European priority issue”
Author: Almaz OhenePublished: 5 April 2017
Prep: Cook: Serves:
Ahead of World Parkinson’s Day on 11 April, Marian Harkin, Member of European Parliament (MEP) declares Parkinson’s “a European priority issue” in front of lawmakers, stakeholders and Parkinson’s campaigners at European Parliament
Speaking at a high-level workshop hosted by the European Parkinson’s Disease Association (EPDA), Marian Harkin, MEP and chair of the European Parliament’s Interest Group on Mental Health, Well-being and Brain Disorders, discussed the “extraordinary impact” of Parkinson’s and called it “a European priority issue”.
Harkin was among the lawmakers, stakeholders and other Parkinson’s activists – including Professor Bastiaan Bloem – who were invited to the workshop held at the European Parliament in Brussels, Belgium, by the EPDA to mark the 200th anniversary of the discovery of Parkinson’s disease.
Just in time for the #UniteForParkinsons campaign, the event brought together 30 members of the Parkinson’s community from EU institutions, Parkinson’s healthcare facilities and several leaders of national Parkinson’s associations, advocating for a stronger policy response to Parkinson’s at the European level and promoting a new Parkinson’s rating scale developed by the EPDA and its partners.
Commenting on the responsibility of the EU institutions, Harkin said: “The extent of Parkinson’s in Europe – and the extraordinary impact it has on people with the disease and their families – makes this a European priority issue. I strongly believe that patient empowerment is the most effective way to manage this and other neurodegenerative conditions, and the EU can take a leadership role on this front.”
Professor Bastiaan Bloem, medical director of the Parkinson Center Nijmegen in the Netherlands, presented a talk on the future of Parkinson’s healthcare partnerships. He acknowledged that Parkinson’s disease is here for the next few decades and that while others are working on the cure, he is working on the care in the form of the multi-disciplinary treatment programme ParkinsonNet, of which he is a co-founder.
He said: “An integrated healthcare approach enables leaps in the levels to better quality of care with fewer disease complications. The cost of Parkinson’s healthcare in the Netherlands is going down by €30 million each year”.
“The extent of Parkinson’s in Europe – and the extraordinary impact it has on people with the disease and their families – makes this a European priority issue”
Knut-Johan Onarheim, president of the EPDA, said: “This year marks the 200-year anniversary of the discovery of Parkinson’s by James Parkinson. There are more than 1.2 million people living with this appalling condition in Europe, a number that is set to double by 2030. Rising prevalence is compounded by significant hurdles to timely diagnosis and individualised treatment and care, including a lack of education of non-specialist clinicians and poor coordination between members of the multidisciplinary healthcare team.
“People also face unacceptable levels of social stigma and discrimination when they remain in full-time employment. It is time to turn political support into policy action, and do better for people with Parkinson’s and their families.”
During a panel debate moderated by Donna Walsh, executive director at the European Federation for Neurological Disease Associations (EFNA), the My PD Journey group identified several areas where the EU could play a leading role in coordinating an ambitious and coordinated policy response to Parkinson’s:
1. Enhancing access to timely diagnosis, appropriate treatments, individualised care and essential social services.
2. Empowering patients to take an active role in decisions about their treatments and care pathways by promoting a bottom-up approach to healthcare.
3. Improving employment conditions and reducing social stigma.
4. Addressing fragmented healthcare and sharing good practices across Member States.
5. Supporting quality of life and cure research through continued funding.
My PD Journey
‘My PD Journey’ is a multi-stakeholder European coalition – led by the EPDA –working towards improving the lives of people living with Parkinson’s disease. Their mission is to enable tailored care for people with Parkinson’s throughout their journey. The initiative involves representatives across the entire Parkinson’s disease community – including European umbrella healthcare organisations, people with Parkinson’s, carers and members of the multidisciplinary healthcare team.
With regard to the EU’s ambitions in the area of employment and social policies in particular, Emmanuelle Grange, from the European Commission, said: “Community-based care and independent living, better accessibility to products and services, non-discrimination in access to employment, and reasonable accommodation at work are key factors that contribute to a better quality of life for people with Parkinson disease and their families. Joint efforts of EU institutions, Member States, economic actors and patient groups are essential to achieve concrete improvements in these areas.”
The EPDA pledged to continue to advocate for a stronger policy response from the EU and national governments, and will work closely with its members, representatives of the EU institutions and its partners to achieve its objectives in the short, medium and long-term.
Lewy body dementia: “The worst of Parkinson’s and Alzheimer’s together”
Shedding light on the dementia often mistaken for Parkinson’s
5 days ago
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”
Could a specialised smartwatch support people with Parkinson’s disease?
A specialised smartwatch, which could help those living with Parkinson’s to better manage their condition, will be rolled out to thousands of people in England. The Parkinson’s Kinetigraph, developed by the National Health Service (NHS) in Plymouth and the University of Plymouth, UK, contains sensors designed to monitor the wearer’s activity and buzz with medication reminders. Data collected from the watch – which detects excessive movement, immobility and sleep disturbances – is shared with healthcare providers, allowing for improvements to physiotherapy and prescriptions based on patient needs. Commenting on the smartwatch’s launch, NHS England chief executive Amanda Pritchard said: “Not only is it better for these people living with Parkinson’s, but it is also more efficient for the NHS, freeing up space and time in hospitals for our hard-working staff.” UK health secretary Sajid Javid, meanwhile, described the Kinetigraph as a “fantastic example of how technology is driving cutting-edge innovation…